1. ODX Knowledgebase
  2. Your Clinical Questions

What are the potential clinical implications of markedly elevated myeloperoxidase (i.e., levels >2700 pmol/L)?

Consider this observation in the presence of elevated oxidized LDL, homocysteine, and ferritin.

Myeloperoxidase (MPO) is a valuable biomarker of oxidative stress and such a markedly elevated level (greater than 2700 pmol/L) reflects not only increased oxidative stress but a high risk of vascular inflammation, endothelial dysfunction, and increased vulnerability of plaque to erosion and rupture.

MPO generates reactive species that oxidize various components of LDL including its lipid, protein, and antioxidant components. Antioxidant nutrients vitamins C and E can help prevent this oxidation.

Over time, reference ranges for MPO have been revised and currently, levels below 420 pmol/L are recommended.

The combination of elevated biomarkers described in your question suggests someone with a high risk of cardiovascular disease.

Teng, Nathaniel et al. “The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.” Redox report : communications in free radical research vol. 22,2 (2017): 51-73. 

Ramachandra, Chrishan J A et al. “Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection.” Antioxidants & redox signaling vol. 32,15 (2020): 1135-1149. 

Ndrepepa, Gjin. “Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease.” Clinica chimica acta; international journal of clinical chemistry vol. 493 (2019): 36-51. 

Cleveland Heart Lab. Myeloperoxidase. https://www.clevelandheartlab.com/wp-content/uploads/2013/09/MPO-Practitioner-One-Pager-CHL-D006b.pdf